THNR株価予想とETF分析 - 配当・運用報酬・保有銘柄・NAV・RSI・MACD

THNR

Amplify Weight Loss Drug & Treatment ETF

終値 10月23日 3:59 PM ET (韓国 10/24 04:59)

$24.70

-0.25 ▼ -1.00%

拡大型レジスタンス 28.17 サポート 23.50 維持 2日間同じ線 AIが引いた参考線です。外れることがあるため参考程度に。予測ではありません。

詳細指標テーブル

Category ⓘ	Global or ExUS Equities - Industry Sector	Expense ⓘ	0.59%	Return% 1Y ⓘ	7.92%	Total Holdings ⓘ	22	Perf Week ⓘ	0.8%	Volume ⓘ	385
Asset Type ⓘ	Equities (Stocks)	AUM ⓘ	$6M	Return% 3Y ⓘ	-	NAV ⓘ	$24.95	Perf Month ⓘ	-3.82%	Avg Volume ⓘ	0.00M
ETF Type ⓘ	Global Equities	Dividend TTM ⓘ	$0.41 (1.67%)	Return% 5Y ⓘ	-	52W High ⓘ	-11.6%	Perf Quarter ⓘ	-4.09%	Rel Volume ⓘ	0.3
Active/Passive ⓘ	Passive	Div Gr. 3/5Y ⓘ	-	Return% 10Y ⓘ	-	52W Low ⓘ	7.91%	Perf Half Y ⓘ	0.91%	Prev Close ⓘ	$24.95
IPO ⓘ	2024/5/21	Flows% 1M ⓘ	0%	Return% SI ⓘ	0.32%	RSI (14) ⓘ	45.86	Perf YTD ⓘ	-2.06%	Price ⓘ	$24.70
Beta ⓘ	0.43	Flows% 3M ⓘ	15.21%	Flows% YTD ⓘ	115.58%	Flows% 1Y ⓘ	115.58%	Perf Year ⓘ	6.65%	Volatility(W/M) ⓘ	0.27% 0.99%
SMA20 ⓘ	0.16%	SMA50 ⓘ	-4.01%	SMA200 ⓘ	-2.54%	ATR ⓘ	0.36

ETF 紹介

Amplify Weight Loss Drug & Treatment ETFTHNR | NYSE | 一般ETF 集中分析を見る

Amplify Weight Loss Drug & Treatment ETF seeks investment results that generally correspond to the performance (before fees and expenses) of the VettaFi Weight Loss Drug & Treatment Index. The fund's manager invests at least 80% of its net assets (plus borrowings for investment purposes) in securities that comprise the index. The index is comprised of global companies who are manufacturers in the GLP-1 agonist pharmaceutical business or who enable such business. GLP-1 agonists (glucagon-like peptide) seek to lower blood sugar levels and reduce appetite and promote fullness, with the ultimate potential for weight loss. The fund is non-diversified.

THNR ETFをひと目で

0.59% 低いほど有利

$6M 運用資産

22銘柄

1.67%

上場日 2024年

運用方式指数連動

運用会社 Amplify

上位保有銘柄 22銘柄保有

上位3銘柄で 100%を占めます

少数の銘柄に偏っています。それらが揺れるとETFも一緒に揺れます。